Work with Us
NCATS aims to address common barriers in clinical and translational research that scientists nationwide face every day, with the goal of delivering more treatments to more patients more quickly.
Contact the Division of Clinical Innovation
NCATS programs support a broad range of clinical research, including clinical trials. NCATS authorization (PDF - 133KB) limits specific support for clinical trials only through the end of Phase IIA.
Phase II clinical trials are designed to test drugs for efficacy (or effectiveness) and side effects in a limited number of patients. Phase IIA trials provide data for exposure-response in patients, while Phase IIB trials provide data for dose-ranging in patients.
Addressing Clinical Research Challenges
Researchers nationwide face common barriers in clinical and translational research that can delay the development of new interventions for patients in need. These challenges include:
- Difficulties in recruiting, mentoring and retaining a critical mass of qualified clinical and translational investigators
- Increased research costs and complexity
- Low patient recruitment and retention in clinical research studies
- Inflexible study designs
- Increased regulatory burdens
NCATS supports innovative programs, such as the Clinical and Translational Science Awards (CTSA) Program and Rare Diseases Clinical Research Network (RDCRN), to help address these challenges.